development & production

Commercialization of protein-based vaccines & biopharmaceuticals

Free
Message: How disappointed would you be...

Good results are not build into the price because there are 3 LOU's that if effects. Ofcorse there is speculation that they should be good based on all the previous studies on ferrets and NVAX phase I trials.

We know the technology works, the question is how well compared to the others. In my opinion it will be class leading based on previous studies. The target is $ 2+ with class leading technology and more MOU's unannouned yet that depends on phase I.

You seriously can't think the results are built into .70 -.80 cent range, Yes if we were trading at 1.50. I would say it is built in but not at .70 -.80

Share
New Message
Please login to post a reply